Epitranscriptomic control of cancer hallmarks: Functions, mechanisms, and therapeutics of RNA modifications.
The epitranscriptome, comprising over 170 distinct RNA modifications, represents a dynamic and multifaceted layer of gene regulation.
APA
Deng X, Wu D, et al. (2026). Epitranscriptomic control of cancer hallmarks: Functions, mechanisms, and therapeutics of RNA modifications.. Cancer cell, 44(1), 50-76. https://doi.org/10.1016/j.ccell.2025.12.001
MLA
Deng X, et al.. "Epitranscriptomic control of cancer hallmarks: Functions, mechanisms, and therapeutics of RNA modifications.." Cancer cell, vol. 44, no. 1, 2026, pp. 50-76.
PMID
41448180
Abstract
The epitranscriptome, comprising over 170 distinct RNA modifications, represents a dynamic and multifaceted layer of gene regulation. These chemical marks such as N-methyladenosine (mA), 5-methylcytosine (mC), and pseudouridine (Ψ) modulate RNA processing, localization, stability, and translation, shaping cell identity and stress responses. In cancer, RNA modifications integrate with oncogenic signaling networks to influence cancer cell proliferation, metabolism, immune evasion, stemness, and therapeutic resistance. Recent advances in detection technologies, functional perturbation tools, and spatial profiling have accelerated our understanding of the epitranscriptome's roles and the underlying mechanisms in malignancies. In this review, we provide a mechanistic framework connecting RNA modifications and regulators to the hallmarks of cancer. We highlight emerging insights into the interface between epitranscriptomic regulators and canonical cancer pathways and evaluate their potential as biomarkers and therapeutic targets. Together, these findings underscore RNA modification as a pivotal regulatory axis in cancer biology and a promising frontier for translational intervention.
MeSH Terms
Humans; Neoplasms; RNA Processing, Post-Transcriptional; Transcriptome; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Animals; Adenosine
같은 제1저자의 인용 많은 논문 (5)
- IL-6 regulates the polarization of Dectin-1 macrophages to weaken immune escape in thyroid cancer.
- Self-Assembled Carrier-Free Nanomedicines Potentiate Chemo-Photothermal Immunotherapy by Overcoming Prostaglandin E2-Mediated Immunosuppression.
- Short- and long-term outcomes after laparoscopic and open liver resection for combined hepatocellular-cholangiocarcinoma patients: a propensity score-matched study.
- Steroid receptor co-activator 3 and cancer: a hormonal to non-hormonal story.
- Discovery of a novel napabucasin derivative B16 as a potent STAT3 inhibitor for the treatment of triple-negative breast cancer.